AstraZeneca PLC Ordinary Shares (AZN)
EBITDA Growth
22.45%
TTM · Period ending:
AZN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported22.45%period ending
Latest reported22.45%period ending
AZN TTM EBITDA YoY % (22.61% → 22.45%)
Year-over-year change
High-resolution chart · PNG
AZN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 63.4684% | |
| 64.7656% | |
| -22.9646% | |
| 96.9126% | |
| 11.649% | |
| 32.3072% | |
| 3,104.8421% | |
| 27.7998% | |
| 177.0651% | |
| -3.6659% | |
| -91.1869% | |
| -68.4167% | |
| -75.8155% | |
| -40.6559% | |
| -43.8934% | |
| 80.3404% | |
| 131.9084% | |
| 2,611.2478% | |
| 1,053.6977% | |
| 603.7951% | |
| 1,364.8923% | |
| -110.1729% | |
| -130.204% | |
| -80.3486% | |
| -90.9745% | |
| 28.4818% | |
| 22.6124% |